Results 101 to 110 of about 57,449 (202)

Practical guidance for navigating buprenorphine discontinuation. [PDF]

Harm Reduct J
Sonoda K, Hilmer AB, Bello JK.
europepmc   +1 more source

An Experimental Study to Evaluate the Role of Buprenorphine, Morphine, and Naltrexone in Animal Models of Depression. [PDF]

Cureus
Suja Nongtdu NL, Verma V.
europepmc   +1 more source

Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial [PDF]

Dylan Rose Balter, Lisa B. Puglisi, James Dziura, David A. Fiellin, Benjamin A. Howell   +4 more
openalex   +1 more source

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper [PDF]

Kelsey Armeni, Laura C. Chambers, Alyssa Peachey, Justin Berk, Kirsten J. Langdon, Lisa A. Peterson, Francesca L. Beaudoin, Rachel Wightman   +7 more
openalex   +1 more source

Postpartum retention in opioid agonist treatment for opioid dependence: A population-based cohort study. [PDF]

Arch Womens Ment Health
Zhou J, Varney B, Jones N, Bharat C, Degenhardt L, Havard A, Tran DT.   +6 more
europepmc   +1 more source

Implementation facilitation improves readiness for emergency department-initiated buprenorphine to treat opioid use disorder. [PDF]

J Subst Use Addict Treat
Strout T, Dziura J, Barrett TW, Cowan E, Hawk KF, Herring AA, Manteuffel J, Martel S, Owens PH, McCormack RP, Perrone J, Fiellin DA, D'Onofrio G, Edelman EJ.   +13 more
europepmc   +1 more source

Buprenorphine Treatment Duration and Adherence Among Youth and Subsequent Health Outcomes. [PDF]

Pediatrics
Hadland SE, Kimmel SD, Yan S, Bettano AL, Lo-Ciganic WH, Bagley SM, Calihan JB, Hsu HE, Larochelle MR.   +8 more
europepmc   +1 more source

Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study. [PDF]

Addict Behav Rep
Costa GPA, Suh R, Sofuoglu M, De Aquino JP.   +3 more
europepmc   +1 more source

Mobile addiction treatment units: a narrative review. [PDF]

Addict Sci Clin Pract
Barrera I, Wang G, Rajakumar B, Muthupalaniappan S, Cronin AE, Chatterjee A.   +5 more
europepmc   +1 more source

Buprenorphin [PDF]

, 2018
C. Vidal, W. R. Külpmann
openaire   +1 more source